CoChat

KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond

Open access
Nagasaka, Misako, Potugari, Bindu, Nguyen, Alexis, Sukari, Ammar, Azmi, Asfar S, Ou, Sai-Hong Ignatius · 2021 · Cancer Treatment Reviews
Cited by 76

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Kirsten rat sarcoma viral oncogene homolog (KRAS) is a proto-oncogene of the RAS-MAPK pathway. KRAS mutations are present in a variety of malignancies including lung, colorectal, and pancreatic cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted therapy for KRAS has resulted in poor prognosis of patients with tumors harboring KRAS mutations. While the conditional approval of sotorasib was a major breakthrough for those patients harboring KRAS G12C mutations, G12C only accounts for a fraction of those with KRAS mutations and eventual resistance to G12C inhibitors are unavoidable. This comprehensive review on KRAS inhibitors covers accumulating evidence on not only the G12C inhibitors but also other therapeutic attempts to tackle KRAS including combination therapy as well as direct inhibition with vaccines, adoptive T cell therapy, proteolysis-targeted chimeras (PROTACs) and CRISPR/Cas9.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ctrv.2021.102309

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 29

  1. El Osta, 2019, Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium Experience, J Thorac Oncol, 14, 876, 10.1016/j.jtho.2019.01.020 · DOI · Paper page
  2. Biernacka, 2016, The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma, Cancer Genet, 209, 195, 10.1016/j.cancergen.2016.03.001 · DOI · Paper page
  3. Ostrem, 2016, Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design, Nat Rev Drug Discov, 15, 771, 10.1038/nrd.2016.139 · DOI · Paper page
  4. Nagasaka, 2020, KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?, Cancer Treat Rev, 84, 101974, 10.1016/j.ctrv.2020.101974 · DOI · Paper page
  5. Heymach, 2004, Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer, Ann Oncol, 15, 1187, 10.1093/annonc/mdh315 · DOI
  6. Yam, 2018, A phase II study of tipifarnib and gemcitabine in metastatic breast cancer, Invest New Drugs, 36, 299, 10.1007/s10637-018-0564-2 · DOI
  7. Sharma, 2002, A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan, Ann Oncol, 13, 1067, 10.1093/annonc/mdf173 · DOI
  8. Meier, 2012, Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV, Gynecol Oncol, 126, 236, 10.1016/j.ygyno.2012.04.050 · doi:10.1016/j.ygyno.2012.04.050
  9. Kim, 2005, Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma, Cancer, 104, 561, 10.1002/cncr.21188 · DOI
  10. Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest New Drugs, 33, 720, 10.1007/s10637-015-0212-z · DOI · Paper page
  11. NDA/BLA Multi-disciplinary Review and Evaluation {NDA 214665} LUMAKRASTM (sotorasib). 214665Orig1s000MultidisciplineR.pdf (fda.gov) Last accessed July 19, 2021.
  12. Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Presented as a poster at AACR 2021 (abstract number 1259). · DOI · Paper page
  13. Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients with advance pancreatic cancer: results of a phase I/II study. Int J Cancer 1996; 65(4):450-453. doi: 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E. · doi:10.1002/(sici)1097-0215(19960208)65:4<450::aid-ijc10>3.0.co;2-e
  14. Schwartzentruber, 2011, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma, N Engl J Med, 364, 2119, 10.1056/NEJMoa1012863 · DOI · Paper page
  15. Lindinger, 2003, Induction of murine ras oncogene peptide-specific T cell responses by immunization with plasmid DNA-based minigene vectors, Vaccine, 21, 4285, 10.1016/S0264-410X(03)00486-9 · DOI
  16. Weng, 2014, DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model, Gene Ther, 21, 888, 10.1038/gt.2014.67 · DOI
  17. Goff, 2016, Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma, J Clin Oncol, 34, 2389, 10.1200/JCO.2016.66.7220 · DOI · Paper page
  18. Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 · DOI · Paper page
  19. Rosenberg, 2011, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin Cancer Res, 17, 4550, 10.1158/1078-0432.CCR-11-0116 · DOI · Paper page
  20. Lu, 2017, Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3, J Clin Oncol, 35, 3322, 10.1200/JCO.2017.74.5463 · DOI · Paper page
  21. Robbins, 2015, A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response, Clin Cancer Res, 21, 1019, 10.1158/1078-0432.CCR-14-2708 · DOI · Paper page
  22. Zacharakis, 2018, Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer, Nat Med, 24, 724, 10.1038/s41591-018-0040-8 · DOI · Paper page
  23. Tran, 2015, Immunogenicity of somatic mutations in human gastrointestinal cancers, Science, 350, 1387, 10.1126/science.aad1253 · DOI · Paper page
  24. Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 2018;3:pii: 122467. doi: 10.1172/jci.insight.122467. · DOI · Paper page
  25. Cafri, 2019, Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients, Nat Commun, 10, 449, 10.1038/s41467-019-08304-z · DOI · Paper page
  26. Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J Immunother, 36, 133, 10.1097/CJI.0b013e3182829903 · DOI · Paper page
  27. Scudellari, 2019, Protein-slaying drugs could be the next blockbuster therapies, Nature, 567, 298, 10.1038/d41586-019-00879-3 · DOI
  28. Cheng, 2020, Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer, J Med Chem, 63, 7892, 10.1021/acs.jmedchem.0c00929 · DOI · Paper page
  29. Bannoura SF, Uddin MH, Nagasaka, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021 Sep 9. doi: 10.1007/s10555-021-09990-2. Online ahead of print. · DOI

Cited by

Metadata

Authors
Nagasaka, M., Potugari, B., Nguyen, A., Sukari, A., Azmi, A. S., & Ou, S.-H. I.
Venue
Cancer Treatment Reviews
Publisher
Elsevier BV
Published
2021-12
Volume
101
Pages
102309
ISSN
0305-7372 (ISSN-L)
OpenAlex
W3210374936
Cited by
76
References
33
FWCI
3.56
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • National Cancer Institute (R01CA24060701, R37 5R37CA215427)
  • Sky Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.